Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment
Guihong Liu, Tao Chen, Zhenyu Ding, et al.
Cell Proliferation (2021) Vol. 54, Iss. 4
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

Targeting the tumor stroma for cancer therapy
Maosen Xu, Tao Zhang, Ruolan Xia, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 156
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Seyedehdelaram Ghalehbandi, Jale Yüzügülen, Md Zahidul Islam Pranjol, et al.
European Journal of Pharmacology (2023) Vol. 949, pp. 175586-175586
Open Access | Times Cited: 129
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Yun Liu, Yang Li, Yuxi Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 101
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87
Angiogenesis after ischemic stroke
Jie Fang, Zhi Wang, Chao‐Yu Miao
Acta Pharmacologica Sinica (2023) Vol. 44, Iss. 7, pp. 1305-1321
Closed Access | Times Cited: 71
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Ruiwen Ruan, Li Li, Xuan Li, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 50
Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies
Anchal Pathak, Ajay Kumar Pal, Subhadeep Roy, et al.
Stem Cells International (2024) Vol. 2024, Iss. 1
Open Access | Times Cited: 16
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
Sareshma Sudhesh Dev, Syafiq Asnawi Zainal Abidin, Reyhaneh Farghadani, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 93
Role of Cytokines and Chemokines in Angiogenesis in a Tumor Context
Mannon Geindreau, Mélanie Bruchard, Frédérique Végran
Cancers (2022) Vol. 14, Iss. 10, pp. 2446-2446
Open Access | Times Cited: 68
The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets
Siarhei A. Dabravolski, Victoria A. Khotina, Andrey V. Omelchenko, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 931-931
Open Access | Times Cited: 67
Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation
Shuai Lu, Xibo Sun, Zhongbao Zhou, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Recent development of VEGFR small molecule inhibitors as anticancer agents: A patent review (2021–2023)
Jing Zeng, Qichuan Deng, Zheng Chen, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107278-107278
Closed Access | Times Cited: 14
Anti‐angiogenesis in colorectal cancer therapy
Zhenni Yang, Xuqian Zhang, Xiaozhe Bai, et al.
Cancer Science (2024) Vol. 115, Iss. 3, pp. 734-751
Open Access | Times Cited: 13
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Hyaluronan-decorated copper-doxorubicin-anlotinib nanoconjugate for targeted synergistic chemo/chemodynamic/antiangiogenic tritherapy against hepatocellular carcinoma
Gang Tan, Guanghui Hou, Junmin Qian, et al.
Journal of Colloid and Interface Science (2024) Vol. 662, pp. 857-869
Closed Access | Times Cited: 9
Integrating Single-Cell and Spatial Transcriptomics to Uncover and Elucidate GP73-Mediated Pro-Angiogenic Regulatory Networks in Hepatocellular Carcinoma
Jiazhou Ye, Xing Gao, Xi huang, et al.
Research (2024) Vol. 7
Open Access | Times Cited: 8
Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023)
Minseok Song, Ahmed Elkamhawy, Woojeong Noh, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 1
Closed Access | Times Cited: 1
Inhibitory effects of carbohydrazide indole derivative on micro-blood vessel growth using ex vivo, in vivo, and in vitro assays
Bayan Jamal Khaleel, H. Salman, Haitham Mahmood Kadhim, et al.
In Vitro Cellular & Developmental Biology - Animal (2025)
Closed Access | Times Cited: 1
Natural Products: A Promising Therapeutics for Targeting Tumor Angiogenesis
Ruyi Li, Xin Song, Junming Guo, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 45
Supramolecular Polymer‐Nanomedicine Hydrogel Loaded with Tumor Associated Macrophage‐Reprogramming polyTLR7/8a Nanoregulator for Enhanced Anti‐Angiogenesis Therapy of Orthotopic Hepatocellular Carcinoma
Xiang Liu, Yini Huangfu, Jing-Rong Wang, et al.
Advanced Science (2023) Vol. 10, Iss. 22
Open Access | Times Cited: 21
A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy
Weixin Zhang, Jiao Huang, Xin-Yi Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115673-115673
Closed Access | Times Cited: 21
Advances in targeted therapy and immunotherapy for esophageal cancer
Haiou Yang, Xuewei Li, Wenhui Yang
Chinese Medical Journal (2023) Vol. 136, Iss. 16, pp. 1910-1922
Open Access | Times Cited: 18
Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via METTL3-mediated RAC3 m6A modification
Mengmeng Chen, Qicheng Zhang, Sijia Zheng, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 5, pp. 1616-1632
Open Access | Times Cited: 17
Exploring Immune Redox Modulation in Bacterial Infections: Insights into Thioredoxin-Mediated Interactions and Implications for Understanding Host–Pathogen Dynamics
Omer M. A. Dagah, Billton Bryson Silaa, Minghui Zhu, et al.
Antioxidants (2024) Vol. 13, Iss. 5, pp. 545-545
Open Access | Times Cited: 7
Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies
Rasha M. Hassan, Islam H. Ali, Ahmed M. El Kerdawy, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107728-107728
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top